Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Posts Mild Q3 Revenue Growth from Life Science and Clinical Dx Segments

NEW YORK, Nov. 5 (GenomeWeb News) - Bio-Rad Laboratories yesterday reported increased revenues for the third quarter from its life science and clinical diagnostic business segments, while its earnings declined.


Bio-Rad booked $258.8 million in revenues for the quarter ended Sept. 30, compared with $241.8 million during the same period last year. Its life science segment contributed $120.6 million in revenues, up 7 percent over last year's receipts, driven by a mix of products geared more towards reagents and increased sales of multiplex array technology, amplification and electrophoresis reagents, and gene transfer technology.


Life science also benefited from gene expression products from MJ GeneWorks and MJ Research, which Bio-Rad acquired in August.


Bio-Rad spent $26.6 million during the quarter on R&D, up from $23 million during the same period last year.


Net income fell to $6.3 million, or $.24 per share, from $9.7 million, or $.37 per share, during the third quarter of 2003.


As of Sept. 30, Bio-Rad had $125.2 million in cash and cash equivalents.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.